Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danish Mazhar

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Future Oncology (London, England)|September 17, 2011
Role of chemotherapy in upper urinary tract urothelial cell cancersAmy Kwan, Danish Mazhar
Nature Clinical Practice. Urology|September 5, 2008
Early chemotherapy in prostate cancerDanish Mazhar, Jonathan Waxman
Future Oncology (London, England)|January 19, 2017
The evolving role of chemotherapy in prostate cancerSuliman Boulos, Danish Mazhar
Future Oncology (London, England)|October 26, 2013
Second-line systemic therapy for metastatic urothelial carcinoma of the bladderChristina Ann Ortmann, Danish Mazhar
Nature Reviews. Urology|April 5, 2012
Urologic oncology: Poor trial accrual hinders germ cell tumor therapy advancesMichael V Williams, Danish Mazhar
BJU International|September 19, 2006
Improving outcomes in early prostate cancer: Part II--neoadjuvant treatmentDanish Mazhar, Sarah Ngan, Jonathan Waxman
Future Oncology (London, England)|February 7, 2007
Neoadjuvant chemotherapy for bladder transitional cell carcinoma: a new standard of care?Danish Mazhar, Nasim Ali, Sarah Ngan
Future Oncology (London, England)|October 6, 2010
Long-term cardiovascular risk following platinum-based chemotherapy for germ cell tumorsClary Evans, Michael Williams, Danish Mazhar
Expert Review of Anticancer Therapy|August 24, 2006
What's the (end) point of cancer vaccines?Mark Bower, Danish Mazhar, Justin Stebbing
BJU International|September 19, 2006
Improving outcomes in early prostate cancer: Part I--adjuvant treatmentDanish Mazhar, Sarah Ngan, Jonathan Waxman
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Future Oncology (London, England)|September 17, 2011
Role of chemotherapy in upper urinary tract urothelial cell cancersAmy Kwan, Danish Mazhar
Nature Clinical Practice. Urology|September 5, 2008
Early chemotherapy in prostate cancerDanish Mazhar, Jonathan Waxman
Future Oncology (London, England)|January 19, 2017
The evolving role of chemotherapy in prostate cancerSuliman Boulos, Danish Mazhar
Future Oncology (London, England)|October 26, 2013
Second-line systemic therapy for metastatic urothelial carcinoma of the bladderChristina Ann Ortmann, Danish Mazhar
Nature Reviews. Urology|April 5, 2012
Urologic oncology: Poor trial accrual hinders germ cell tumor therapy advancesMichael V Williams, Danish Mazhar
BJU International|September 19, 2006
Improving outcomes in early prostate cancer: Part II--neoadjuvant treatmentDanish Mazhar, Sarah Ngan, Jonathan Waxman
Future Oncology (London, England)|February 7, 2007
Neoadjuvant chemotherapy for bladder transitional cell carcinoma: a new standard of care?Danish Mazhar, Nasim Ali, Sarah Ngan
Future Oncology (London, England)|October 6, 2010
Long-term cardiovascular risk following platinum-based chemotherapy for germ cell tumorsClary Evans, Michael Williams, Danish Mazhar
Expert Review of Anticancer Therapy|August 24, 2006
What's the (end) point of cancer vaccines?Mark Bower, Danish Mazhar, Justin Stebbing
BJU International|September 19, 2006
Improving outcomes in early prostate cancer: Part I--adjuvant treatmentDanish Mazhar, Sarah Ngan, Jonathan Waxman
Pageof 5